and conjugated estrogens. Here, these treatment options are compared with regard to their mechanism of action, and onset and duration of efficacy. An extensive review of the clinical trials that ...

Most of the studies that evaluated estrogens limited duration of administration to five consecutive days. Adverse effects of long-term administration of conjugated estrogens in males, therefore ...

I am a 66-year-old white male who is active and relatively healthy. I have recently been diagnosed with prostate cancer. One ...

The antibody-drug conjugate improved progression-free survival for patients previously treated with hormone therapy.

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...